CLINICAL CASE STUDY: JOSEPH R. (Original PDF from Publisher)

The posttransplant administration of cyclophosphamide to prevent both graft-vs-host and hostvs-graft alloreactivity has revolutionized the practice of hematopoietic cell transplantation
(HCT). The eligibility boundaries for consideration of HCT have expanded, and now include
patients with a suitable haploidentical donor, instead of an HLA-identical sibling donor. This
case study provides not only a simulation of treatment choices for a patient with multiple
myeloma and end-stage renal disease, but also the background science that is helpful in
understanding the clinical situation.
AABB thanks Thomas Spitzer, MD, for development of this case study.